sod2

SOD2 (Superoxide Dismutase 2, Manganese)

SOD2 encodes the only superoxide dismutase resident in the mitochondrial matrix — it converts superoxide radical (O2•-) generated by the electron transport chain to hydrogen peroxide (H2O2), sequestering mtROS at their point of production. Critically, it is the first line of defense at the inner mitochondrial membrane and is non-redundant: cytosolic sod1 and extracellular SOD3 cannot substitute for it. Loss-of-function is lethal in rodents within days of birth. In aging biology, SOD2 sits at the mechanistic intersection of the mitochondrial-dysfunction and cellular-senescence hallmarks — its aging-associated decline (driven by reduced sirt3 activity) permits superoxide accumulation that drives oxidative DNA damage, p16^INK4a induction, and senescent-cell accumulation in post-mitotic and slowly renewing tissues.

Identity

• UniProt: P04179 (SODM_HUMAN)
• NCBI Gene: 6648
• HGNC symbol: SOD2
• Ensembl: ENSG00000112096
• Mouse ortholog: Sod2 (one-to-one; ~90% sequence identity; phenotypically essential across both species)
• Length: 222 amino acids (including 24-residue mitochondrial targeting sequence, cleaved on import)
• Cofactor: Mn(2+) — one ion per subunit; required for catalytic activity (EC 1.15.1.1)
• Active form: Homotetramer in the mitochondrial matrix

Function

SOD2 catalyzes:

2 O2•- + 2 H+ → H2O2 + O2

Superoxide (O2•-) is produced primarily by Complex I and Complex III of the ETC as a byproduct of electron leak — estimates suggest 0.1–2% of oxygen consumed by mitochondria is incompletely reduced to superoxide rather than water ¹. This flux is low under physiological conditions but rises substantially with aging, caloric excess, and ETC dysfunction. SOD2 is the only enzyme in the mitochondrial matrix capable of dismutating superoxide; the resulting H2O2 is then neutralized by peroxiredoxin 3 (PRDX3), glutathione peroxidases, and catalase (in peroxisomes) ².

The Val16Ala polymorphism (rs4880) in the mitochondrial targeting sequence alters import efficiency, with the Ala allele associated with more efficient import and higher matrix SOD2 activity. This variant is the primary GWAS instrument for population-genetic studies of SOD2 function.

Regulation

SIRT3-mediated deacetylation (primary aging-relevant control)

sirt3 (a mitochondrial NAD+-dependent deacylase) directly activates SOD2 by deacetylating Lys-68 and Lys-122 ³. Qiu 2010 identifies both as “two critical lysine residues” without specifying a primary/secondary hierarchy; both are required for full activation. Acetylation at these residues suppresses catalytic activity; SIRT3-mediated deacetylation restores it. This is the mechanistic link between the SIRT3 aging-decline axis and mitochondrial superoxide management:

• Caloric restriction elevates SIRT3 → deacetylates SOD2 → reduces mitochondrial ROS ³
• Aging-associated decline in NAD+ → reduced SIRT3 activity → SOD2 hyperacetylation → impaired superoxide dismutation → elevated mtROS

The SIRT3–SOD2 axis is part of the broader sirtuin longevity-signaling network. FAM177A1 disrupts this SIRT3–SOD2 signaling axis to drive mitochondrial dysfunction in vascular contexts (PMID 41943851, 2026). needs-replication in aging models specifically.

FOXO3 transcriptional activation

foxo3 directly transcribes SOD2 by binding FOXO response elements (FREs) in the SOD2 promoter. When the insulin-igf1 / pi3k-akt-pathway axis is suppressed (fasting, oxidative stress), FOXO3 translocates to the nucleus and drives antioxidant gene expression including SOD2 and catalase ⁴. This couples nutrient status to mitochondrial superoxide defense. Consistent with this, the IIS-FOXO-SOD2 axis has been characterized as a “core anti-aging pathway” conserved from termite queens to mammals (PMID 42042474, 2026).

Additional PTMs

• Tyr-58 nitration — under high superoxide flux or peroxynitrite exposure, Tyr-58 is nitrated, which inhibits catalytic activity and creates a positive-feedback amplification of oxidative stress.
• Lys polyubiquitination — targets SOD2 for proteasomal degradation; USP36 deubiquitinase counteracts this, stabilizing the protein ².

Knockout phenotypes

Sod2-/- (complete knockout) — neonatal lethality

Two independent groups generated homozygous Sod2-null mice within months of each other in 1995–1996, demonstrating SOD2 is indispensable:

• Li et al. 1995 — Sod2-/- mice die within 10 days of birth from dilated cardiomyopathy (massive cardiac enlargement, mitochondrial structural damage in cardiomyocytes) ⁵.
• Lebovitz et al. 1996 — complementary line showed neonates survived up to ~3 weeks and displayed neurodegeneration of basal ganglia and brainstem neurons, severe anemia, and myocardial injury; the differing primary phenotype reflects the different genetic backgrounds and possibly slightly different knockout constructs ⁶.

Both knockouts establish that mitochondrial superoxide, if unchecked, is lethal in rapidly metabolizing tissues — heart and brain consume the most oxygen per unit mass and are thus most vulnerable to superoxide accumulation.

Dimension	Status
Pathway conserved in humans?	yes — SOD2 equally essential in human mitochondria; no viable human SOD2 null exists
Phenotype conserved in humans?	yes (functional) — rare human SOD2 loss-of-function variants are associated with cardiomyopathy and mitochondrial disease, mirroring the mouse KO
Replicated in humans?	partial — loss-of-function disease phenotypes parallel; aging-context direct evidence from tissue-specific models only

Sod2-heterozygous (+/-) — key null result for free-radical theory

Van Remmen et al. 2003 — the most important aging experiment with this gene — tested whether a 50% lifetime reduction in MnSOD activity shortens lifespan:

Heterozygous Sod2+/- mice (50% MnSOD activity in all tissues, lifelong) showed identical mean and maximum lifespan to WT controls, despite having significantly elevated oxidative DNA damage (8-oxodG, 15–60% higher across tissues at 26 months) and a 100% increase in tumor incidence by age 26 months ⁷. (n per group not stated in abstract; full text closed-access no-fulltext-access)

This result is a direct challenge to the strong form of the free-radical theory of aging (Harman 1956): if chronic elevation of mitochondrial oxidative damage from birth does not shorten lifespan, then oxidative damage is not the primary determinant of aging rate. The tumor incidence increase confirms elevated DNA damage is biologically consequential — but the pathway to cancer diverges from the pathway to aging here.

Interpretation caveats: (1) 50% residual SOD2 may be sufficient to prevent rate-limiting oxidative damage for lifespan — complete deficiency may be required; (2) compensatory upregulation of cytosolic SOD1, catalase, or glutathione peroxidases could mask oxidative contributions; (3) the result does not exclude roles for SOD2 in tissue-specific healthspan or functional outcomes (muscle, skin) even if lifespan is unaffected. contradictory-evidence

Conditional Sod2 knockout (skin epidermis) — Velarde 2012/2015

Tissue-specific deletion of Sod2 in the skin epidermis recapitulates key hallmarks of aged skin:

Velarde et al. 2012 — Sod2-/- skin (CD1 background, neonatal): all 9 KO mice showed SA-β-gal positivity (vs 1/8 WT); two-fold increase in p16^INK4a; elevated γH2AX (nuclear DNA damage); impaired mitochondrial complex II activity; epidermal thinning + increased terminal differentiation; no increase in apoptosis ⁸. Senescent cells were epidermal, not dermal. Natural aging (C57BL/6J) showed parallel complex-II decline and p16+ accumulation. This paper provides the strongest in-vivo causal evidence that mtROS → senescence in a specific tissue.

Velarde et al. 2015 (PMID 26240345) — Follow-up with conditional adult deletion of Sod2 in epidermal stem cells revealed age-dependent pleiotropic effects: in young mice, Sod2 deficiency accelerated wound closure (via increased differentiation); in aged mice, the same deficiency impaired wound closure and caused epidermal stem cell exhaustion ⁹. This age-context dependency is an important complication — mitochondrial ROS are not simply harmful at all ages, consistent with mitohormesis.

Aging biology

Aging-associated decline in SOD2 activity

SOD2 protein expression and activity decline with age in multiple tissues, in parallel with:

1. Age-associated fall in NAD+ → reduced SIRT3 activity → SOD2 hyperacetylation
2. Transcriptional suppression as FOXO3 is increasingly sequestered by elevated IIS tone in aged tissues
3. Post-translational inactivation via Tyr-58 nitration from rising peroxynitrite levels

This creates a positive feedback: declining SOD2 → elevated O2•- → more oxidative damage → further SIRT3/FOXO3 impairment → further SOD2 decline.

Role in cellular senescence induction

The Velarde 2012 causal chain is now the standard mechanistic model connecting mitochondrial-dysfunction to cellular-senescence:

mtROS (O2•-) → nuclear DNA damage (8-oxodG, DSBs) → DDR activation → p16^INK4a/p21^CIP1 → CDK4/6 inhibition → Rb hypophosphorylation → permanent cell-cycle arrest → sasp → chronic-inflammation

SOD2 deficiency is sufficient to initiate this chain in vivo in a tissue context. The SASP component then amplifies inflammation via nf-kb activation, providing the link to the chronic-inflammation hallmark.

Superoxide theory of aging — SOD2 as the test case

Van Remmen 2003’s null-lifespan result (see above) is the most commonly cited evidence against the strong superoxide theory of aging. The field’s current consensus is that mitochondrial ROS plays a signaling role (mitohormesis; see mitohormesis) at low levels and a damaging role at high levels — but the dose-response transition, and what determines which tissue/cell type tips into chronic damage vs adaptive signaling, remains incompletely characterized. no-mechanism for the regulatory switch.

SOD2 mimetics (pharmacology)

Because SOD2 is a protein, not a small molecule, it is not directly “druggable” in the classical sense — but SOD-mimetic compounds that mimic its catalytic function have been developed:

Compound	Class	Status	Notes
MnTBAP	Mn-porphyrin, SOD/catalase mimetic	Research probe only	Non-cell-permeable; poor CNS penetration; not clinically viable
EUK-134 / EUK-189	Mn-salen complexes	Research probe	Used to rescue Sod2-/- mice in Velarde 2012; not clinical-stage
GC4419 / avasopasem	Mn-pentaazamacrocycle, selective SOD mimetic	Phase 3 completed 2025	Highly selective for superoxide dismutation; 10^8 M-1s-1 rate constant

Avasopasem (GC4419) — Phase 3 ROMAN trial (2025): In head-and-neck cancer patients receiving concurrent chemoradiotherapy, avasopasem met its primary endpoint of SOM incidence reduction (54% vs 64%; p=0.045) and also significantly reduced SOM duration (median 8 vs 18 days; p=0.002). However, the pre-specified secondary endpoint of grade-4 oral mucositis incidence did not reach significance (27% reduction; p=0.052), and grade-4 OM days were also not significantly reduced (p=0.143). Because the primary endpoint effect was smaller than predicted by Phase 2b and the key secondary endpoint failed, the FDA requested a confirmatory Phase 3 trial rather than grant approval ¹⁰. As of 2026, one active early-phase trial (NCT07137871, Phase 1) is ongoing for avasopasem + CDK4/6 inhibitor in breast cancer.

Phase 2B context: The earlier Anderson et al. 2019 Phase IIb trial demonstrated more striking efficacy at 90 mg — SOM duration median 1.5 vs 19 days (p=0.024), incidence 43% vs 65% (p=0.009), grade-4 incidence 16% vs 30% (p=0.045) ¹¹. The diminished Phase 3 effect size was unexpected and may reflect patient-selection or dose differences.

Aging relevance of avasopasem: The current clinical programme is entirely in the radioprotection/oncology context. No trials target aging-related oxidative stress directly. Demonstrating SOD-mimetic efficacy in an aging outcome would require an independent trial programme.

Cancer biology note

SOD2 has a well-documented context-dependent dual role in cancer: tumor suppressor in some tissues (where superoxide from the Fenton reaction is pro-apoptotic) and tumor promoter in others (where H2O2 generated by SOD2 drives invasion and metastasis via altered redox signaling). The Hempel et al. 2011 review (doi:10.2174/187152011795255911) synthesizes this ambiguity. This complicates therapeutic targeting — elevated SOD2 in cancer cells may confer chemotherapy resistance by quenching superoxide generated by radiotherapy and redox-active drugs.

Limitations and gaps

• #gap/needs-gtex-aging-rho — Spearman ρ for age-correlation across GTEx tissues not yet populated; priority tissues: skeletal muscle, heart, skin.
• #gap/needs-human-replication — All causal mtROS → senescence evidence is from mouse models or cell culture. Direct human tissue evidence (e.g., SOD2 activity measurement in aged vs young biopsies with senescence co-staining) is lacking.
• #gap/dose-response-unclear — SOD2 exhibits mitohormesis at low superoxide flux; the threshold between beneficial signal and damaging accumulation is not defined for any human tissue.
• #gap/contradictory-evidence — Van Remmen 2003 null-lifespan result in Sod2+/- mice is in tension with the aging-context mechanistic model; the field has not fully reconciled whether SOD2 decline is a driver or a correlate of aging rate.
• #gap/no-mechanism — Regulatory switch between mitohormesis (low-level superoxide = beneficial) and pathological ROS accumulation (high-level = damaging) not mechanistically characterized.
• #gap/long-term-unknown — Long-term effects of SOD-mimetic supplementation in healthy aging humans are unknown; no aging-indication trial has been conducted.

Pathway membership

• sirtuin — SIRT3 deacetylates SOD2 (primary activating PTM)
• insulin-igf1 / pi3k-akt-pathway — FOXO3 upstream; suppressed by IIS → reduces SOD2 transcription
• oxphos — SOD2 is the immediate downstream buffer for Complex I/III superoxide leak
• mitochondrial-dynamics — mitochondrial fusion/fission dynamics affect mtROS distribution and SOD2 access

Cross-references

• sirt3 — deacetylates Lys-68 and Lys-122 (both critical per Qiu 2010); primary enzymatic activator
• foxo3 — transcribes SOD2 in nucleus under low-IIS/stress conditions
• bnip3 — upstream mitophagy regulator; failure to clear damaged mitochondria increases SOD2 substrate load
• oxphos — Complex I/III produce SOD2’s substrate (O2•-)
• mitochondrial-biogenesis — PGC-1α drives SOD2 transcription in exercise/CR response
• mitohormesis — low-level O2•- is a hormetic signal; SOD2 quenches it
• sasp — downstream of SOD2 loss → senescence → SASP
• mitochondrial-dysfunction — SOD2 decline is a mechanistic node within this hallmark
• cellular-senescence — downstream effect of SOD2 loss (Velarde 2012 evidence)
• velarde-2012-mitochondria-skin-senescence — anchor study for SOD2-senescence causal chain

Footnotes

Footnotes

1. Chance B, Sies H, Boveris A · Physiol Rev 1979;59:527–605 · doi:10.1152/physrev.1979.59.3.527 · review · widely-cited estimate that 0.1–2% of mitochondrial O2 consumption yields superoxide — specific percentages should be treated as estimates dependent on ETC substrate state · model: isolated mitochondria (multiple species) ↩

2. UniProt P04179 (SODM_HUMAN), Swiss-Prot manually curated entry, accessed 2026-05-19. Function summary, PTM annotations, and subcellular localization sourced here. ↩ ↩²

3. doi:10.1016/j.cmet.2010.11.015 · Qiu X, Brown K, Hirschey MD, Verdin E, Chen D · Cell Metab 2010;12:662–667 · in-vivo (mouse, Sirt3-/-) + biochemistry · caloric restriction activates SIRT3 → deacetylates Lys-122 and Lys-68 on SOD2 → increases antioxidant activity; Sirt3-/- mice lose CR-mediated ROS protection · model: Sirt3-/- + Sirt3-/+ mouse; biochemical deacetylation assays ↩ ↩²

4. doi:10.1016/bs.acr.2016.01.004 · Germain D · Adv Cancer Res 2016;130:211–256 · review · SIRT3, FOXO transcription factors, and estrogen receptors as regulators of mitochondrial UPR and antioxidant gene expression (including SOD2) in cancer and aging context ↩

5. doi:10.1038/ng1295-376 · Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ · Nat Genet 1995;11:376–381 · in-vivo (mouse, Sod2-/-) · dilated cardiomyopathy and neonatal lethality; establishes necessity of SOD2 for early survival · model: Sod2-/- (mixed background) ↩

6. doi:10.1073/pnas.93.18.9782 · Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, Huang S, Matzuk MM · PNAS 1996;93:9782–9787 · in-vivo (mouse, Sod2-/-) · neurodegeneration of basal ganglia/brainstem neurons, severe anemia, perinatal death up to ~3 weeks; complementary KO line to Li 1995 · model: Sod2-/- (mixed background) ↩

7. doi:10.1152/physiolgenomics.00122.2003 · Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, et al. · Physiol Genomics 2003;16:29–37 · in-vivo (mouse, Sod2+/-) · n per group not stated in abstract needs-replication (n=~100/group is unverified; full PDF is closed-access) · heterozygous MnSOD reduction (50%) does not shorten lifespan despite elevated 8-oxodG (15–60% higher across tissues at 26 months) and 100% increase in tumor incidence — critical null result for strong free-radical theory of aging · model: Sod2+/- on C57BL/6 × DBA/2 background ↩

8. velarde-2012-mitochondria-skin-senescence · Sod2-/- histology/SOD2-Western n=8 WT/9 KO; senescence Westerns n=6 WT/6 KO; aging cohort n=6/10/13 at 4/8/24mo; in-vitro keratinocyte/fibroblast quadruplicates · in-vivo + in-vitro · p<0.05 (SA-βgal, Fisher Exact) · model: CD1 Sod2-/- mouse (17–20 days postnatal) + C57BL/6J aging cohort + human keratinocytes (AG21837) + fibroblasts (HCA2) ↩

9. doi:10.1073/pnas.1505675112 · Velarde MC, Demaria M, Melov S, Campisi J · PNAS 2015;112:E4227–E4236 · in-vivo (mouse, conditional epidermal Sod2 KO) · pleiotropic age-dependent effects: Sod2 deficiency accelerates wound closure in young mice but delays it + exhausts epidermal stem cells in aged mice · model: conditional epidermal Sod2-/- (K5-Cre × Sod2-flox) ↩

10. doi:10.1016/j.eclinm.2025.103539 · Anderson C, Lee CM, Kelley JR, Walker GV, et al. · EClinicalMedicine 2025 · randomized, Phase 3 (ROMAN) · n=407 (241 avasopasem / 166 placebo) primary analysis population · primary endpoint met: SOM incidence reduced (54% vs 64%; p=0.045); SOM duration reduced (median 8 vs 18 days; p=0.002) · secondary endpoint failed: grade-4 OM incidence not significantly reduced (27% reduction; p=0.052); grade-4 OM days p=0.143 · FDA requested confirmatory trial (primary effect smaller than Phase 2b predicted; key secondary failed) · model: human clinical trial (HNC, Phase 3) ↩

11. doi:10.1200/JCO.19.01507 · Anderson CM, Lee CM, Saunders DP, Curtis A, Dunlap N, et al. · J Clin Oncol 2019;37:3256–3265 · randomized, double-blind, Phase IIb · n=223 · GC4419 90 mg reduced SOM duration (median 1.5 vs 19 days; p=0.024), incidence (43% vs 65%; p=0.009), and grade-4 severity (16% vs 30%; p=0.045) in head-and-neck cancer chemoradiotherapy · model: human clinical trial (HNC) ↩